GB1381979A - Amino derivatives of quinoline quinoxaline and quinazoline - Google Patents

Amino derivatives of quinoline quinoxaline and quinazoline

Info

Publication number
GB1381979A
GB1381979A GB919672A GB919672A GB1381979A GB 1381979 A GB1381979 A GB 1381979A GB 919672 A GB919672 A GB 919672A GB 919672 A GB919672 A GB 919672A GB 1381979 A GB1381979 A GB 1381979A
Authority
GB
United Kingdom
Prior art keywords
reacting
quinazoline
compounds
ethylenediamine
feb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB919672A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Original Assignee
PFIZER Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE795970D priority Critical patent/BE795970A/xx
Application filed by PFIZER Ltd filed Critical PFIZER Ltd
Priority to GB919672A priority patent/GB1381979A/en
Priority to AU51985/73A priority patent/AU471598B2/en
Priority to SE7302024A priority patent/SE417204B/xx
Priority to IE236/73A priority patent/IE37519B1/xx
Priority to US332485A priority patent/US3890319A/en
Priority to FI436/73A priority patent/FI63757C/fi
Priority to MX129473U priority patent/MX3042E/es
Priority to ES411804A priority patent/ES411804A1/es
Priority to JP48020280A priority patent/JPS5754516B2/ja
Priority to CA164,361A priority patent/CA981678A/en
Priority to AR246774A priority patent/AR213705A1/es
Priority to DE19732309160 priority patent/DE2309160A1/de
Priority to ES412102A priority patent/ES412102A1/es
Priority to CH293873A priority patent/CH576975A5/xx
Priority to CH149075A priority patent/CH577500A5/xx
Priority to NL7302799.A priority patent/NL159102B/xx
Priority to FR7307157A priority patent/FR2181776B1/fr
Publication of GB1381979A publication Critical patent/GB1381979A/en
Priority to US05/613,808 priority patent/US4029792A/en
Priority to JP9493480A priority patent/JPS5625176A/ja
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GB919672A 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline Expired GB1381979A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
BE795970D BE795970A (fr) 1972-02-29 Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
AU51985/73A AU471598B2 (en) 1972-02-29 1973-02-08 2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents
SE7302024A SE417204B (sv) 1972-02-29 1973-02-13 Sett att framstella nya kinoxalin- och kinazolinderivat
IE236/73A IE37519B1 (en) 1972-02-29 1973-02-14 Novel amino derivatives of quinoxaline and quinazoline
US332485A US3890319A (en) 1972-02-29 1973-02-14 (2-imidazolin-2-y(amino) substituted quinolines, -quinoxalines and -quinazolines as antihypertensive agents
FI436/73A FI63757C (fi) 1972-02-29 1973-02-14 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat
MX129473U MX3042E (es) 1972-02-29 1973-02-15 Procedimiento para preparar derivados de quinoxalina o - quinazolina de 2 - imidazolin - 2 ilaminas
ES411804A ES411804A1 (es) 1972-02-29 1973-02-20 Procedimiento para la obtencion de derivados de quinoxalinay quinazolina.
JP48020280A JPS5754516B2 (forum.php) 1972-02-29 1973-02-21
CA164,361A CA981678A (en) 1972-02-29 1973-02-22 (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents
AR246774A AR213705A1 (es) 1972-02-29 1973-02-23 Procedimiento para preparar(2-imidazolin-2-ilamino)-quinolinas,quinoxalinas y-quinazolinas sustituidas
DE19732309160 DE2309160A1 (de) 1972-02-29 1973-02-23 2-imidazolin-2-yl-amino-substituierte, benzokondensierte, heterocyclische verbindungen und arzneipraeparate
ES412102A ES412102A1 (es) 1972-02-29 1973-02-27 Procedimiento para la obtencion de derivados de quinoxalinay quinazolina.
CH293873A CH576975A5 (forum.php) 1972-02-29 1973-02-28
CH149075A CH577500A5 (forum.php) 1972-02-29 1973-02-28
NL7302799.A NL159102B (nl) 1972-02-29 1973-02-28 Werkwijze voor het bereiden van een farmaceutisch preparaat met bloeddrukverlagende werking en onder toepassing daarvan verkregen gevormd preparaat, alsmede werkwijze voor het bereiden van een verbinding, geschikt voor toepassing bij voornoemde werkwijze.
FR7307157A FR2181776B1 (forum.php) 1972-02-29 1973-02-28
US05/613,808 US4029792A (en) 1972-02-29 1975-09-16 (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
JP9493480A JPS5625176A (en) 1972-02-29 1980-07-11 Manufacture of novel quinaxaline or quinazoline derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
GB5162972 1972-11-08

Publications (1)

Publication Number Publication Date
GB1381979A true GB1381979A (en) 1975-01-29

Family

ID=26242776

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919672A Expired GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline

Country Status (16)

Country Link
US (1) US3890319A (forum.php)
JP (2) JPS5754516B2 (forum.php)
AR (1) AR213705A1 (forum.php)
AU (1) AU471598B2 (forum.php)
BE (1) BE795970A (forum.php)
CA (1) CA981678A (forum.php)
CH (2) CH577500A5 (forum.php)
DE (1) DE2309160A1 (forum.php)
ES (2) ES411804A1 (forum.php)
FI (1) FI63757C (forum.php)
FR (1) FR2181776B1 (forum.php)
GB (1) GB1381979A (forum.php)
IE (1) IE37519B1 (forum.php)
MX (1) MX3042E (forum.php)
NL (1) NL159102B (forum.php)
SE (1) SE417204B (forum.php)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145421A (en) 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US8513249B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US9186358B2 (en) 2009-11-18 2015-11-17 Galderma Laboratories, L.P. Combination therapy for treating or preventing an inflammatory skin disorder
US10201517B2 (en) 2010-10-21 2019-02-12 Galderma Laboratories, L.P. Brimonidine gel compositions and methods of use

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
US4486432A (en) * 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS6118950U (ja) * 1984-07-10 1986-02-03 財団法人鉄道総合技術研究所 トロリ線の給油装置
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan, Inc. Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CZ285481B6 (cs) * 1993-12-17 1999-08-11 The Procter & Gamble Company 6-(2-imidazolinylamino)chinolinové sloučeniny použitelné jako alfa-2-adrenoceptorové agonisté
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CZ175496A3 (en) * 1993-12-17 1996-11-13 Procter & Gamble 6-(2-imidazolinylamino)quinoxaline compounds usable as alpha-2 adrenoceptor agonists
DE69500313T2 (de) * 1994-02-08 1997-11-06 Alcon Laboratories, Inc., Fort Worth, Tex. Neues verfahren zur herstellung von clonidin-derivaten
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
HUP0002966A3 (en) * 1996-11-25 2001-10-29 Procter & Gamble 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
ES2225998T3 (es) * 1996-11-25 2005-03-16 THE PROCTER & GAMBLE COMPANY Compuestos (2-imidazolinilamino)indol utiles como agonistas del adrenorreceptor alfa 2.
AU5433898A (en) * 1996-11-25 1998-06-22 Procter & Gamble Company, The 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
NZ336010A (en) 1996-11-25 2001-05-25 Procter & Gamble Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
ATE271048T1 (de) 1997-11-24 2004-07-15 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2001273269B2 (en) 2000-07-14 2005-08-11 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
ATE380551T1 (de) * 2002-10-08 2007-12-15 Allergan Inc Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
WO2004032913A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
KR100953246B1 (ko) * 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
BRPI0511519A (pt) 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法,組合物及套組
RU2592703C9 (ru) 2005-11-15 2016-10-20 Эррей Байофарма Инк. ИНГИБИТОРЫ ТИПА ErbB
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
EP3584237B1 (en) 2009-10-06 2020-12-09 Allergan, Inc. Alpha adrenergic receptor modulators
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2555748A2 (en) 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
JP2013523825A (ja) 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科製剤のための保存剤組成物の組み合わせ
CA2807084C (en) 2010-07-29 2018-05-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
WO2013016178A1 (en) 2011-07-25 2013-01-31 Allergan, Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
US4145421A (en) 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
US8586586B2 (en) 2003-05-27 2013-11-19 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7838563B2 (en) 2003-05-27 2010-11-23 Galderma Laboratories Inc. Compounds, formulations, and methods for ameliorating telangiectasias
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US8426410B2 (en) 2003-05-27 2013-04-23 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US8993571B2 (en) 2003-05-27 2015-03-31 Galderma Laboratories, L.P. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US9186358B2 (en) 2009-11-18 2015-11-17 Galderma Laboratories, L.P. Combination therapy for treating or preventing an inflammatory skin disorder
US9072739B2 (en) 2009-11-19 2015-07-07 Galderma Laboratories, L.P. Method for treating psoriasis
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513249B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9861631B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9861632B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8163725B1 (en) 2010-10-21 2012-04-24 Galderma R&D SNC Gel compositions and methods of use
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US10201517B2 (en) 2010-10-21 2019-02-12 Galderma Laboratories, L.P. Brimonidine gel compositions and methods of use

Also Published As

Publication number Publication date
FI63757C (fi) 1983-08-10
JPS5625176A (en) 1981-03-10
AR213705A1 (es) 1979-03-15
FR2181776A1 (forum.php) 1973-12-07
BE795970A (fr) 1973-08-27
DE2309160A1 (de) 1973-09-27
FR2181776B1 (forum.php) 1976-08-13
US3890319A (en) 1975-06-17
AU471598B2 (en) 1976-04-29
MX3042E (es) 1980-03-04
JPS5745439B2 (forum.php) 1982-09-28
AU5198573A (en) 1974-08-08
IE37519L (en) 1973-08-29
ES412102A1 (es) 1976-05-16
JPS5754516B2 (forum.php) 1982-11-18
CA981678A (en) 1976-01-13
NL159102B (nl) 1979-01-15
CH576975A5 (forum.php) 1976-06-30
IE37519B1 (en) 1977-08-17
ES411804A1 (es) 1976-05-01
FI63757B (fi) 1983-04-29
NL7302799A (forum.php) 1973-08-31
JPS4897878A (forum.php) 1973-12-13
CH577500A5 (forum.php) 1976-07-15
SE417204B (sv) 1981-03-02

Similar Documents

Publication Publication Date Title
GB1381979A (en) Amino derivatives of quinoline quinoxaline and quinazoline
IE38886B1 (en) Heterocyclic compounds
GB1358680A (en) Pyrrolo-3,4-b-pyrazine derivatives
IE44166L (en) Nontropine benzilate derivatives.
GB1309182A (en) Pyrimidine derivatives
GB1173942A (en) New 2,3-Dihydro-1,4-Benzoxazines
GB1426070A (en) Piperazine derivatives
GB1290818A (forum.php)
GB1278272A (en) Substituted hexahydro-imidazoquinolines
GB1252847A (forum.php)
GB1510764A (en) Piperidinoalkyl derivatives of purines
GB1253915A (en) Novel pyridoindole derivatives and a process, for the manufacture thereof
GB1530074A (en) Rho-acetamidophenol derivatives the preparation thereof and the use of such derivatives as therapeutic agents
GB1258797A (forum.php)
GB1186495A (en) 0-[3-(4-Fluorobenzoyl) Proplyl]-4-Substituted Piperazines, their Acid Addition Salts and their method of preparation
GB1276968A (en) Improvements in or relating to phenylacetamides and the preparation thereof
GB1299201A (en) Medicaments derived from thiazolidine carboxylic acid
GB1229509A (forum.php)
GB1233938A (forum.php)
GB1299421A (en) 3-substituted amino-6-hydrazino-pyridazines
GB1254270A (en) Benzoxazepine derivatives
GB1432577A (en) Substituted indolin-2-ones
GB1146183A (en) Improvements in or relating to nicotinamide derivatives having an analgesic, anti-inflammatory, antipyretic and anti-histaminic action, method for their preparation, andtherapeutical use
GB1422831A (en) Acylaminobenzimidazole derivatives
ES464068A1 (es) Procedimiento para la obtencion de derivados de quinclona

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
429A Application made for amendment of specification (sect. 29/1949)
429H Application (made) for amendment of specification now open to opposition (sect. 29/1949)
429D Case decided by the comptroller ** specification amended (sect. 29/1949)
SPA Amended specification published
PCNP Patent ceased through non-payment of renewal fee